Evidence map›Paper›PMID 28402723›Full record

ArticleCancer biology & therapy2017

Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.

Annalisa Pezzolo, Angela Rita Sementa, Margherita Lerone, Martina Morini, Marzia Ognibene, Raffaella Defferrari, Katia Mazzocco, Massimo Conte, Anna Rita Gigliotti, Alberto Garaventa and 2 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Cancer biology & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Neuroblastoma Patients' Outcome and Chromosomal Instability.International journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Oncotarget · 2018
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Annalisa Pezzoloa Laboratorio di Oncologia , Istituto Giannina Gaslini , Genova , Italy.
Angela Rita Sementab Laboratorio di Anatomia Patologica , Istituto Giannina Gaslini , Genova , Italy.
Margherita Leronec Laboratorio di Genetica Molecolare , Istituto Giannina Gaslini , Genova , Italy.
Martina Morinid Laboratorio di Biologia Molecolare , Istituto Giannina Gaslini , Genova , Italy.
Marzia Ognibenea Laboratorio di Oncologia , Istituto Giannina Gaslini , Genova , Italy.
Raffaella Defferrarib Laboratorio di Anatomia Patologica , Istituto Giannina Gaslini , Genova , Italy.
Katia Mazzoccob Laboratorio di Anatomia Patologica , Istituto Giannina Gaslini , Genova , Italy.
Massimo Contee Dipartimento di Emato-Oncologia , Istituto Giannina Gaslini , Genova , Italy.
Anna Rita Gigliottie Dipartimento di Emato-Oncologia , Istituto Giannina Gaslini , Genova , Italy.
Alberto Garaventae Dipartimento di Emato-Oncologia , Istituto Giannina Gaslini , Genova , Italy.
Vito Pistoiaf Area Immunologica Ospedale Pediatrico Bambino Gesù , Roma.ORCID 0000-0003-0528-9563
Luigi Varesiod Laboratorio di Biologia Molecolare , Istituto Giannina Gaslini , Genova , Italy.
Istituto Giannina Gaslini · ITBambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuroblastoma (NB) is a common and often lethal cancer of early childhood that accounts for 10% of pediatric cancer mortality. Incidence peaks in infancy and then rapidly declines, with less than 5% of cases diagnosed in children and adolescents ≥ 10 y. There is increasing evidence that NB has unique biology and an chronic disease course in older children and adolescents, but ultimately dismal survival.

methodsWe describe a rare constitutional 3p26.3 terminal microdeletion which occurred in an adolescent with NB, with apparently normal phenotype without neurocognitive defects. We evaluated the association of expression of genes involved in the microdeletion with NB patient outcomes using R2 platform. We screened NB patient's tumor cells for CHL1 protein expression using immunofluorescence.

resultsConstitutional and tumor DNA were tested by array-comparative genomic hybridization and single nucleotide-polymorphism-array analyses. Peripheral blood mononuclear cells from the patient showed a 2.54 Mb sub-microscopic constitutional terminal 3p deletion that extended to band p26.3. The microdeletion 3p disrupted the CNTN4 gene and the neighboring CNTN6 and CHL1 genes were hemizygously deleted, each of these genes encode neuronal cell adhesion molecules. Low expression of CNTN6 and CNTN4 genes did not stratify NB patients, whereas low CHL1 expression characterized 417 NB patients having worse overall survival. CHL1 protein expression on tumor cells from the patient was weaker than positive control.

conclusionThis is the first report of a constitutional 3p26.3 deletion in a NB patient. Since larger deletions of 3p, indicative of the presence of one or more tumor suppressor genes in this region, occur frequently in neuroblastoma, our results pave the way to the identification of one putative NB suppressor genes mapping in 3p26.3.

Indexed as

Chromosome DeletionAdolescentChromosomes, Human, Pair 3Comparative Genomic HybridizationHumansIn Situ Hybridization, FluorescenceLeukocytes, MononuclearMaleNeuroblastomaPhenotype3p26.3 microdeletion3p terminal deletion syndromeArray-CGHgermline structural chromosomal abnormalitiesneuroblastoma

Identifiers

PMID28402723
PMCPMC5499752
OpenAlexW2605728428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.